Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 9/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 6/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 6/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655428 | 0.86 | AURKB (0.46) | NUDT1CHEK1PDCD1CD274AURKA | |
| SCHEMBL16655277 | 0.80 | AURKB (0.44) | NUDT1CHEK1PDCD1CD274AURKA | |
| SCHEMBL16655108 | 0.78 | AURKB (0.42) | NUDT1CHEK1PDCD1CD274AURKA | |
| SCHEMBL29576377 | 0.76 | ELANE (0.41) | — | |
| SCHEMBL1648278 | 0.76 | AURKB (0.48) | AURKAAURKBBRAF | |
| SCHEMBL17926767 | 0.75 | NPC1 (0.46) | — | |
| SCHEMBL23457143 | 0.74 | ELANE (0.39) | — | |
| SCHEMBL16654993 | 0.74 | ELANE (0.39) | — | |
| SCHEMBL29222203 | 0.74 | ELANE (0.39) | CD274 | |
| SCHEMBL1647776 | 0.74 | MAPK14 (0.59) | AURKAAURKBBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440977-B2 | Compositions, uses and methods for their preparation | SHENGYUAN PHARMACEUTICAL GUANGZHOU LTD CO. (CN) | 2016-09-13 | — | — | US | disclosed |
| US-9440977-B2 | Compositions, uses and methods for their preparation | SHENGYUAN PHARMACEUTICAL GUANGZHOU LTD CO. (CN) | 2016-09-13 | — | — | US | disclosed |
| EP-3057972-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION | Jin, V (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20160229855-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION | Jin, Bohan (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229855-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION | Jin, Bohan (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2015057695-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION | JIN BOHAN (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015057695-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION | JIN BOHAN (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229855-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION | LIPA, PNLIP, LIPC | NUDT1 207/4885CHEK1 4108/4885PDCD1 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.